Influenza virus polymerase inhibitors in clinical developmen... : Current Opinion in Infectious
Diseases Influenza virus polymerase inhibitors in clinical development : Current Opinion in …

Effective antivirals provide crucial benefits during the early phase of an influenza pandemic,
when vaccines are still being developed and manufactured. Currently, two classes of viral …

Favipiravir is a broad-spectrum antiviral that has shown promise in treatment of influenza
virus infections. While emergence of resistance has been observed for many antiinfluenza …

Background A synergistic effect of combination therapy with favipiravir and oseltamivir has
been reported in preclinical models of influenza. However, no data are available on the …

Current influenza antivirals have limitations with regard to their effectiveness and the
potential emergence of resistance. Encouragingly, several new compounds which inhibit the …

Favipiravir (FPV) is a novel antiviral drug acting as a competitive inhibitor of RNA-dependent
RNA polymerase (RdRp), preventing viral transcription and replication. FPV was approved …

Influenza antiviral drugs are important for the control of influenza, most specifically for the
treatment of influenza patients with severe disease following infection with a seasonal …

These findings highlight the importance of continuous surveillance, and assessment of viral
fitness and transmissibility of resistant virus strains. Detection can be challenging, especially …

Vaccines remain the best measure to reduce total influenza burden. However, presently
available influenza vaccines have some limitations that cause a reduced efficacy compared …

ABSTRACT T-705 (favipiravir) is a new antiviral agent in advanced clinical development for
influenza therapy. It is supposed to act as an alternative substrate for the viral polymerase …